

66/0/60
U.S. PTO

Please type a plus sign (+) inside this box → +

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. LA 24 a

First Inventor or Application Identifier Jeffrey A. Robl et al

Title Method for Treating Diabetes Employing...

Express Mail Label No. EM260262812US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification [Total Pages 52]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) [Total Sheets _____]
4. Oath or Declaration [Total Pages 4]
- Newly executed (original or copy)
 - Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

5. Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- Computer Readable Copy
 - Paper Copy (identical to computer copy)
 - Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- Assignment Papers (cover sheet & document(s))
- 37 C.F.R. § 3.73(b) Statement Power of
(when there is an assignee) Attorney
- English Translation Document (if applicable)
- Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- Preliminary Amendment
- Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
- Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- Other: _____

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation Divisional Continuation-in-part (CIP)

of prior application No: _____ / _____

Prior application Information: Examiner _____

Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)			or <input checked="" type="checkbox"/> Correspondence address below
--	---	--	--	---

Name	Burton Rodney BRISTOL-MYERS SQUIBB COMPANY				
Address	P.O. Box 4000				
City	Princeton	State	New Jersey	Zip Code	08543-4000
Country	USA	Telephone	(609) 252-4336	Fax	(609) 252-4526

Name (Print/Type)	Burton Rodney	Registration No. (Attorney/Agent)	22,076
Signature	Burton Rodney		
	Date Sept. 3, 1999		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



Bristol-Myers Squibb Company

P.O. Box 4000 Princeton, NJ 08543-4000 609 921-4000

Patent Department

Case No.: LA24a
Sept. 7, 1999

To the Assistant Commissioner for Patents:
Washington, D.C. 20231

Sir:

Forwarded herewith is a patent application consisting of specification, claims, Declaration, 1 sheet(s) of drawing and Assignment. The title is: METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION

The inventor(s) is (are): Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson and Krishna Kodukula

The filing fee is believed to be as follows:

Basic fee: \$760.00

Additional fees:

Total number of claims in excess of 20, times \$18.00

Number of independent claims minus 3, times \$78.00

Multiple dependent claims (\$260.00)

Total Filing Fee: \$760.00

Please charge the cost of this filing fee to the Deposit Account (19-3880) of the undersigned.

In the event the actual fee differs from that specified above, it is requested that the overpayment or underpayment be credited or charged to the above-stated account number. It is also requested that all other fees incurred in the prosecution of this application, except the issue fee, be charged to the above-stated account number.

Respectfully submitted,




Burton Rodney
Attorney

LA24a

"Express Mail" mailing label number: **EM260262812US**

Date of Deposit: September 7, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Burton Rodney
Reg. No. 22,076

METHOD FOR TREATING DIABETES EMPLOYING AN aP2
INHIBITOR AND COMBINATION

Field of the Invention

5 The present invention relates to a method for
treating diabetes, especially Type II diabetes, as well as
hyperglycemia, hyperinsulinemia, obesity,
hypertriglyceridemia and related diseases, employing an aP2
inhibitor alone or in combination with another type
10 antidiabetic agent, and to the combination for use in such
method.

Background of the Invention

15 Fatty acid binding proteins (FABPs) are small
cytoplasmic proteins which bind to fatty acids such as
oleic acids which are important metabolic fuels and
cellular regulators. Dysregulation of fatty acid
metabolism in adipose tissue is a prominent feature of
insulin resistance and the transition from obesity to non-
20 insulin dependent diabetes mellitus (NIDDM or Type II
diabetes).

25 aP2, an abundant 14.6 KDa cytosolic protein in
adipocytes, and one of a family of homologous intracellular
fatty acid binding proteins (FABPs), is involved in the
regulation of fatty acid trafficking in adipocytes and
mediates fatty acid fluxes in adipose tissue. G.S.
Hotamisligil et al, "Uncoupling of Obesity from Insulin
Resistance Through a Targeted Mutation in aP2, the
Adipocyte Fatty Acid Binding Protein", Science, Vol. 274,
30 Nov. 22, 1996, pp. 1377-1379, report that aP2-deficient
mice placed on a high fat diet for several weeks developed
dietary obesity, but, unlike control-mice on a similar
diet, did not develop insulin resistance or diabetes.
Hotamisligil et al conclude that "aP2 is central to the
35 pathway that links obesity to insulin resistance"
(Abstract, page 1377).

DIALOG ALERT DBDR928 dates January 2, 1997,
Pharmaprojects No. 5149 (Knight-Ridder Information)
discloses that a major drug company "is using virtual
screening techniques to identify potential new antidiabetic
5 compounds." It is reported that "the company is screening
using aP2, a protein related to adipocyte fatty acid
binding protein."

Description of the Invention

10 In accordance with the present invention, a method
is provided for treating diabetes, especially Type II
diabetes, and related diseases such as insulin resistance,
hyperglycemia, hyperinsulinemia, elevated blood levels of
fatty acids or glycerol, obesity and hypertriglyceridemia
15 wherein a therapeutically effective amount of a drug which
inhibits aP2 (aP2 inhibitor) is administered to a human
patient in need of treatment.

20 In addition, in accordance with the present
invention, a method is provided for treating diabetes and
related diseases as defined above and hereinafter, wherein
a therapeutically effective amount of a combination of an
aP2 inhibitor and another type antidiabetic agent is
administered to a human patient in need of treatment.

25 Furthermore, in accordance with the present
invention, a novel antidiabetic combination is provided
which is formed of a drug which inhibits aP2 and another
type antidiabetic agent which functions by a mechanism
other than by inhibiting aP2. The aP2 inhibitor will be
employed in a weight ratio to the antidiabetic agent
30 (depending upon its mode of operation) within the range
from about 0.01:1 to about 100:1, preferably from about
0.5:1 to about 10:1.

35 The aP2 inhibitors suitable for use in the method of
the invention are compounds which bind to the aP2 protein
and inhibits its function and/or its ability to bind free
fatty acids. The compounds will preferably contain less
than 60 carbon atoms, more preferably less than 45 carbon

atoms, and will contain less than 20 heteroatoms, more preferably less than 12 heteroatoms. They contain a hydrogen bond donator or acceptor group, preferably acidic in nature, which includes, but is not limited to, CO₂H, 5 tetrazole, SO₃H, PO₃H, P(R)(O)OH (where R is lower alkyl or lower alkoxy), OH, NHSO₂R' or CONHSO₂R' (where R' is lower alkyl), and thiazolidindione, and interacts (directly or through an intervening water molecule), either by ionic or hydrogen bonding interactions, with one, two, or three of 10 the three amino acid residues, designated as Arg 106, Arg 126 and Tyr 128 in human aP2, within the aP2 protein.

The compounds suitable for use herein preferably contain an additional substituent, preferably hydrophobic in nature, which include the following groups: alkyl, 15 cycloalkyl, aryl, heteroaryl, cycloheteroalkyl, benzo-fused aryl and heteroaryl, and their substituted counterparts. Especially preferred are aryl and substituted aryl groups. More especially preferred is phenyl and halo or methyl substituted phenyl.

20 The hydrophobic substituent binds to (in) and/or interacts with a discrete pocket within the aP2 protein defined roughly by the amino acid residues Phe 16, Tyr 19, Met 20, Val 23, Val 25, Ala 33, Phe 57, Thr 74, Ala 75, Asp 25 76, Arg 78 in human aP2. The through space distance from the hydrogen bond donor/acceptor group and the additional substituent group is within the distance of about 7 to about 15 Angstroms.

The above compounds may be employed in the form of 30 pharmaceutically acceptable salts thereof and prodrug esters thereof.


Brief Description of Figure

The accompanying Figure is a computer generated image of a partial X-ray structure of compound XVIA 35 (described hereinafter) bound to human aP2.

Detailed Description of the Invention


Examples of aP2 inhibitors suitable for use herein include compounds which include an oxazole or analogous ring. Thus, U.S. Patent No. 5,218,124 to Failli et al (the disclosure of which is incorporated herein by reference) discloses compounds, which have activity as aP2 inhibitors and thus suitable for use herein, which include substituted benzoylbenzene, biphenyl- and 2-oxazole-alkanoic acid derivatives having the following structure:

10



wherein


A is a group having the formula




15

wherein

X is -N- or




Z is



R^1 is hydrogen, lower alkyl or phenyl;

R^2 is hydrogen or lower alkyl; or


25 R^1 and R^2 taken together form a benzene ring, with the proviso that when X is -N-, Z is other than



30 R^3 is hydrogen or lower alkyl;

n is 1-2;

B is




wherein

Y is OR⁵ or N(OH)R⁸;

R⁴ and R⁵ are each, independently, hydrogen or lower alkyl;

R⁶ is hydrogen, halo or nitro;

R⁷ is



R⁸ is lower alkyl;

m is 0-3;

and the pharmacologically acceptable salts thereof.

The grouping A embraces, inter alia, 5- or 6-membered unsaturated nitrogen, sulfur or oxygen containing mono- or benzofused-heterocycles, optionally substituted with lower alkyl or phenyl. The foregoing definition embraces the following heterocyclic moieties; furyl, pyrrolyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, benzofuranyl, benzothienyl, benzothiazolyl, indolyl, benzoxazolyl, quinazolinyl, benzimidazolyl, quinoxaliny, quinazolinyl and the like.

Preferred are the examples where A is defined as above and B is

25


and R⁷ is $\begin{array}{c} \text{---CHCO}_2\text{H} \\ | \\ \text{R}^4 \end{array}$

In another embodiment of the present invention, compounds which have activity as aP2 inhibitors suitable

for use herein are disclosed in U.S. Patent No. 5,403,852 to Barreau et al (which is incorporated herein by reference) which are oxazole derivatives and have the structure

5

II



in which;

R and R' are identical or different and represent a hydrogen atom or an alkyl radical containing 1 or 2 carbon atoms,

10

R₁ and R₂ are identical or different and represent hydrogen or halogen atoms or alkyloxy radicals in which the alkyl portion contains 1 to 4 carbon atoms in a straight or branched chain, and


15

n equals 3 to 6, as well to their salts, to their isomers where they exist and to pharmaceutical compositions containing them.

In addition, other compounds which have activity as aP2 inhibitors suitable for use in the method of the invention are compounds disclosed in U.S. Patent No. 4,001,228 to Mattalia (which is incorporated herein by reference) which are 2-thiol-4,5-diphenyloxazole S-derivatives which have the structure


25

III



wherein m is 0, 1 or 2, n is 1 and R represents hydroxy, alkoxy or amino. Also included within the scope of this invention are salts of the compounds of formula III above, particularly pharmaceutically acceptable addition salts thereof.

Preferred are S-(4,5-diphenyloxazol-2-yl)-mercaptocarboxylic acids of the formula:



- 5 wherein m is 0, 1 or 2, and pharmaceutically acceptable lower alkyl esters and salts thereof.

In another embodiment of the present invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 4,051,250 to Dahm et al (the disclosure of which is incorporated herein by reference) which discloses azole derivatives of the structure

IV




- 15 wherein R₁ is carboxyl, esterified carboxyl or other functionally modified carboxyl group; R₂ and R₃ each are aryl of up to 10 carbon atoms; A is C_nH_{2n} in which n is an integer from 1 to 10, inclusive; and Z is O or S, and the physiologically acceptable salts thereof.

20 Preferred are preferred compounds as disclosed in the Dahm et al patent.


In still another embodiment of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 5,380,854 to Romine et al (the disclosure of which is incorporated herein by reference) and are phenyl-heterocyclic oxazole derivatives which have the structure

V




or pharmaceutically acceptable salt thereof.

Preferred are the compounds where R is $\text{CH}_2\text{CO}_2\text{H}$ and




In yet another embodiment of the method of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in PCT application WO 95/17393 which are diaryloxazole derivatives having the structure

VI



wherein R¹ is carboxy or protected carboxy,

- 5 R² is aryl which may have suitable substituent(s),
 R³ is aryl which may have suitable substituent(s),
 A¹ is lower alkylene,
 A² is bond or lower alkylene and
 -Q- is




- 10 (in which A³ is cyclo (lower)alkane or cycle(lower)alkene, each of which may have suitable substituent(s)).

Preferred are the preferred compounds of WO 95/17393 as illustrated by the working Examples thereof.

- 15 Another embodiment of compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 5,362,879 to Meanwell (the disclosure of which is incorporated herein by reference) which are 4,5-diphenyloxazole derivatives having the structures

20 VIIA




wherein

R is H or C₁-C₅ lower alkyl,

X is N or CH,
Y is H or CO_2R^1 , or COR^2 ,
 R^1 is C₁-C₅ lower alkyl, or phenylmethyl, and
 R^2 is C₁-C₅ alkyl;

5

VIIB




wherein

- R is H or C₁-C₅ lower alkyl,
X is $(\text{CH}_2)_n$ or para or meta substituted phenyl
10 wherein the substituent is OR²,
R² is C₁-C₅ alkyl, and
n is an integer of 4 to 8,
and pharmaceutically acceptable salts thereof.

- Preferred are the preferred compounds of the
15 Meanwell patent as illustrated by the working Examples
thereof.

- In still another embodiment of the present
invention, compounds which have activity as aP2 inhibitors
suitable for use herein are disclosed in U.S. Patent No.
20 5,187,188 to Meanwell (the disclosure of which is
incorporated herein by reference) which are oxazole
carboxylic acid derivatives having the structure

VIII



- 25 wherein

Y and Z are independently hydrogen or together form
a bond;
X is CN, CO_2R^1 or CONR^2R^3 ;

R and R¹ are independently or together H, Na, or C₁-C₅ lower alkyl;


R² and R³ are independently or together H, or C₁-C₅ lower alkyl;

5 or alkali metal salt thereof.

Preferred are the preferred compounds of the above Meanwell patent as illustrated by the working Examples thereof.





In another embodiment of the invention, compounds
10 which have activity as aP2 inhibitors suitable for use herein are disclosed in U.S. Patent No. 5,348,969 to Romine et al (the disclosure of which is incorporated herein by reference) which are phenyloxazolyloxazole derivatives having the structure

15 IX




wherein

x is



Y is CH₃, Ph, or OH, provided that when Y is OH, the
20 compound exists in the keto-enol tautomerism form



R¹ is Ph or Th;

R² is CH₂R³;

R³ is CO₂R⁴;


25 R⁴ is H or C₁-C₅ lower alkyl;

R⁵ is H or CH₃; R⁶ is OHCHN or H₂N; and

R⁷ is H or OH;

or pharmaceutically acceptable salt thereof.


Preferred are the preferred compounds as delineated in the Romine et al patent and in the working Examples thereof, especially where X is




5 and R² is CH₂CO₂H.

In addition, compounds which have activity as aP2 inhibitors which may be employed herein include those disclosed in U.S. Patent No. 5,262,540 to Meanwell (the disclosure of which is incorporated herein by reference) 10 and are 2-(4,5-diaryl)-2-oxazolyl substituted phenoxyalkanoic acids and esters having the structure

XA




XB



15


(wherein n is 7-9 and R is hydrogen or lower alkyl; or when R is hydrogen, the alkali metal salt thereof),

XC



20

XD



wherein

R₁ is phenyl or thienyl;

25 R₂ is hydrogen, lower alkyl or together with CO₂ is tetrazol-1-yl;

X is a divalent connecting group selected from the group consisting of CH_2CH_2 , $\text{CH}=\text{CH}$, and CH_2O ;


Y is a divalent connecting group attached to the 3- or 4-phenyl position selected from the group consisting of 5 OCH_2 , CH_2CH_2 and $\text{CH}=\text{CH}$,

or when R_2 is hydrogen, an alkali metal salt thereof.

Preferred are the preferred compounds as set out in the above Meanwell et al patent as illustrated in the working Examples thereof.

10 In another embodiment of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in PCT application WO 92/04334 which are substituted 4,5-diaryl heterocycles having the formula

XI



15

in which

each group Ar is the same or different and is optionally substituted phenyl or optionally substituted heteroaryl;

20 X is nitrogen or CR^1 ;

Y is nitrogen, $\text{N}(\text{CH}_2)_n\text{A}$ or $\text{C}(\text{CH}_2)_n\text{A}$;

Z is nitrogen, oxygen or $\text{N}(\text{CH}_2)_n\text{A}$, and the dotted line indicates the optional presence of a double bond so as to form a fully unsaturated heterocyclic ring;

25 R^1 is hydrogen, $\text{C}_{1-4}\text{alkyl}$, optionally substituted phenyl or optionally substituted heteroaryl;

n is 4 to 12; and

A is CO_2H or a group hydrolysable to CO_2H ,


30 5-tetrazolyl, SO_3H , $\text{P}(\text{O})(\text{OR})_2$, $\text{P}(\text{O})(\text{OH})_2$, or $\text{P}(\text{O})(\text{R})(\text{OR})$ in which R is hydrogen or $\text{C}_{1-4}\text{alkyl}$, or a pharmaceutically acceptable salt thereof.

Preferred are preferred compounds of WO 92/04334.

In yet another embodiment of the invention, compounds which have activity as aP2 inhibitors suitable

for use herein are disclosed in French Patent 2156486 which have the structure

XII



5 Where X is O or S;

R₁ is H, phenyl or phenyl substituted with F, Cl or Br or alkoxy,


R₂ is H, alkyl, phenyl or phenyl substituted with F, Cl or Br or alkoxy, and

10 R₃ is H or alkyl.

Preferred are those preferred compounds as set out in French Patent No. 2156486.

Most preferred oxazole compounds as aP2 inhibitors are the compounds


15



which may be prepared as disclosed in U.S. Patent No. 5,348,969 to Romine et al.

Another class of aP2 inhibitors suitable for use in the method of the invention include pyrimidine derivatives. Thus, U.S. Patent No. 5,599,770 to Kubota et al (the disclosure of which is incorporated herein by reference) disclose compounds which have activity as aP2 inhibitors and thus suitable for use herein include 2-benzyloxyppyrimidine derivatives having the following structure

XIII




wherein

- R¹ and R² are each independently H, a halogen,
5 hydroxyl, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₅ alkenyl, C₃-C₅ alkynyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₃-C₅ alkenyloxy, C₃-C₅ alkynyloxy, C₁-C₄ alkylthio, or phenyl, with the proviso that at least one of R¹ and R² must be hydroxyl;
- n is an integer of 0 to 5; and
10 each X which may be identical or different if n is greater than 1, is a halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₇-C₉ aralkyloxy, phenyl, hydroxymethyl, hydroxycarbonyl, C₁-C₄ alkoxy carbonyl, or nitro.
- 15 Preferred are the compounds in which either R¹ or R² is hydroxyl and the other R¹ or R² is C₁-C₄ alkyl and X is halogen.


In another embodiment of the method of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in A. Mai et al "Dihydro(alkylthio)-(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series", J. Med. Chem., 1997, 40, 1447-1454 which have the structures

XIVA



3a R=sec-butyl
3b R=cyclopentyl
3c R=cyclohexyl


XIVB




5 X=CH₂
6 X=O
7 X=S

5


XIVC



XIVD



XIVE




R^1 = sec-butyl, cyclopentyl, cyclohexyl;

R^2 = H, CH_3 . The structures XIVA-XIVE are depicted in


5 their keto form. However, it will be apparent to one skilled in the art that they may also exist in their enol form to give structures of the type

XIVF




10 In yet another embodiment of the method of the invention, compounds which have activity as aP2 inhibitors suitable for use herein are disclosed in PCT application WO 96/35678 which are α -substituted pyrimidine-thioalkyl and alkylether compounds which have the structure

XVI



where m is 0 or 1;

R^1 is selected from $-CO_2R_{53}$, $-CONR_{54}R_{55}$,



where s is 0 or 1, and R₂₀, R₂₁, R₂₂, R₂₃, R₂₄, and R₂₅ are the same or different and are selected from -H, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₃-C₈ cycloalkyl, -CF₃, -NO₂, -halo, -OH, -CN, phenyl,

5 phenylthio, -styryl, -CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁), -(CH₂)_n-N(R₃₁)(R₃₂), -C(OH)(R₃₁(R₃₃), -(CH₂)_nN(R₃₁)(CO(R₃₃)), (CH₂)_nN(R₃₁)(SO₂(R₃₃)), or where R₂₀ and R₂₁, or R₂₁ and R₂₂, or R₂₂ and R₂₃ are taken together to form a five or six-

10 membered saturated or unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, -(CH₂)_n-N(R₃₁)(R₃₂), -C₃-C₈ cycloalkyl, -CF₃, -halo, CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁),

15 -(CH₂)_nN(R₃₁)(CO(R₃₃)), -(CH₂)_nN(R₃₁)(SO₂(R₃₃)), -CN, -CH₂CF₃ or -CH(CF₃)₂, or phenyl and the saturated ring may be optionally substituted with 1, 2 or 3, -C₁-C₆ alkyl, -C₁-C₆ alkoxy, -OH, -CH₂OH or -(CH₂)_n-N(R₃₁)(R₃₂) or one oxo (=O);

where n is 0-3 and R₃₁, R₃₂ and R₃₃ are the same or

20 different and are selected from

-H,

C₁-C₆ alkyl,

phenyl optionally substituted with 1, 2 or 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH or -CN,

25 or where R₃₁ and R₃₂ taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(1-C₁-C₆alkyl)piperazinyl, or a member selected from:

30 1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl, 2-benzoxazolyl, 2-benzimidazolyl, 2-oxazolyl, 4-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5-methyl-3-

isoxazolyl, 5-phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-pyrazinyl, 5-methyl-2-pyrazinyl, 6-methyl-2-pyrazinyl, 5-chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2-yl, 2H-1-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, 1-methylimidazol-2-yl, quinoxalin-2-yl, piperon-5-yl, 4,7-dichlorobenzoxazol-2-yl, 4,6-dimethylpyrimidin-2-yl, 4-methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2-methylpyrimidin-4-yl, 4-methylpyrimidin-6-yl, 6-chloropiperon-5-yl, 5-chloroimidazol[1,2-a]pyridin-2-yl, 1-H-inden-3-yl, 1-H-2-methyl-inden-2-yl, 3,4-dihydronaphth-1-yl, S-4-isopropenylcyclohexen-1-yl or 4-dihydronaphth-2-yl; where R₅₃ is selected from -H, C₁-C₆alkyl, C₃-C₆cycloalkyl, phenyl (optionally substituted with 1, 2, or 3-halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH, -CN), or a five or six-membered unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with -H, C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂); where R₅₄ and R₅₅ being the same or different are selected from -H, C₁-C₆ alkyl, allyl, or phenyl (optionally substituted with 1, 2 or 3-halo, C₁-C₆ alkyl, C₁-C₆ alkoxy or -CF₃), or taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(1-C₁-C₆alkyl)piperazinyl;

R₄₁ and R₄₂, being the same or different, are selected from -H and C₁-C₄ alkyl;

R₁₂ is selected from -H, C₁-C₆ alkyl, -C₃-C₆cycloalkyl, -CN, -C(O)NH₂, -C(O)N(C₁-C₆alkyl)(C₁-C₆alkyl), -CO₂H, -CO₂(C₁-C₆alkyl), -CH₂OH, -CH₂NH₂ or -CF₃;

R₁₃ is selected from -H, C₁-C₆ alkyl or -CF₃;

Y is selected from -S-, -S(O)-, -S(O)₂, or -O-;

R₄ is -OH;

R₅ is selected from -H, -C₂H₄OH, -C₂H₄-O-TBDMS, halo, -C₃-C₆cycloalkyl, C₁-C₃ alkoxy, -CH₂CH₂Cl or C₁-C₄ alkyl, with the proviso that R₅ is not isobutyl;

or, when R₆ is hydroxyl, R₄ and R₅ are taken together to form a five or six-membered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidine, furo[2,3-d]pyrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro-thieno[2,3-d]pyrimidine, 1H-pyrazolo[3,4-d]pyrimidine, 1H-purine, pyrimido[4,5-d]pyrimidine, pteridine, pyrido[2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C₁-C₆ alkyl C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂), -C₃-C₈ cycloalkyl, -CF₃, -halo, -CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁), -(CH₂)_nN(R₃₁)(CO(R₃₃)), -(CH₂)_nN(R₃₁)(SO₂(R₃₃)), and the saturated ring may be optionally substituted with 1, 2 or 3, -C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂) or one oxo (=O); and

R₆ is selected from -H, -OH, halo, -CN, -CF₃, -CO₂(R₆₁), -C(O)R₆₁ or -C(O)N(R₆₁)(R₆₂) where R₆₁ and R₆₂ are the same or different and are selected from

-H,
C₁-C₆ alkyl,

phenyl optionally substituted with 1, 2 or 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH, -CN,

or where R₆₁ and R₆₂ taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, or -4-(C₁-C₆ alkyl)piperazinyl; or

pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof.

A preferred embodiment is pyrimidine-thioalkyl and alkylether, where


R₄ is -OH; and

R₆ is selected from -H, halo, -CN, -CF₃, -CO₂(R₁₆), -C(O)R₆₁ or -C(O)N(R₆₁)(R₆₂), preferably CF₃.

A preferred embodiment are compounds of Formula XVI where s is 0 or 1, and Y is -S- or O; more preferably Y is -S-.


Preferred are pyrimidine derivatives of the
5 structures

XVIA



and


XVIB




10

which may be prepared as disclosed in WO 96/35678.

Another embodiment of the method of the invention includes use of aP2 inhibitors which are pyridazinone derivatives. French Patent No. 2,647,676 discloses
15 compounds which have activity as aP2 inhibitors and thus suitable for use herein which have the structures



XVIIA



XVIIIB

where R₁ and R₂ are H, alkyl, aryl or arylalkyl, where the alkyl can include as substituents halogen, CF₃, CH₃O, CH₃S, NO₂, or R₁ and R₂ with the carbons to which they are attached can form methylenedioxy, or
20

R₁ and R₂ can form a C₃-C₇ non-aromatic ring, or a heterocycle which can be pyridine, pyrazine, pyrimidine,


pyridazine, indol, or pyrazole, or an oxygen containing heterocycle which can be pyran or furan, or a sulfur containing heterocycle which can be thiopyran, or thiophene; the heterocycles being optionally substituted 5 with halogen or alkyl,

R₃ and R₄ are H, alkyl, halogen, CF₃, CH₃O, CH₃S or NO₂ or R₃ and R₄ with the carbons to which they are attached can form a methylenedioxy group,

R₅ is H, and

10 Z is a heterocycle which can be pyridine, thiazole, benzothiazole, benzimidazole or quinoline, which Z group can optionally be substituted with halogen or alkyl.

The preferred pyridazinone derivative is



which may be prepared as disclosed in French Patent No. 2,647,676.

Preferred aP2 inhibitors for use herein will include an oxazole ring.

20 Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 40 carbons, preferably 1 to 20 carbons, more preferably 1 to 12 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1 to

4 substituents such as halo, for example F, Br, Cl or I or CF₃, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, acyl, 5 heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio.

Unless otherwise indicated, the term "cycloalkyl" 10 as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons 15 forming the rings, preferably 4 to 12 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,

20




any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, 25 alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio.


Unless otherwise indicated the term "aryl" or "Ar" 30 as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl) and may optionally include one to three additional rings 35 fused to Ar (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings) and may be optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl,

alkoxy, haloalkoxy, alkenyl, trifluoromethyl,
 trifluoromethoxy, alkynyl, cycloalkylalkyl,
 cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl,
 arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio,
 5 arylazo, heteroarylalkyl, heteroarylalkenyl,
 heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano,
 amino, substituted amino wherein the amino includes 1 or 2
 substituents (which are alkyl, aryl or any of the other
 aryl compounds mentioned in the definitions), thiol,
 10 alkylthio, arylthio, heteroarylthio, arylthioalkyl,
 alkoxyarylthio, alkylcarbonyl, arylcarbonyl,
 alkylaminocarbonyl, arylaminocarbonyl, alkoxy carbonyl,
 aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
 alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
 15 arylsulfinylalkyl, arylsulfonylamino or
 arylsulfonaminocarbonyl.

Unless otherwise indicated the term "aralkyl",
 "aryl-alkyl" or "aryllower alkyl" as used herein alone or
 as part of another group refers to alkyl groups as
 20 discussed above having an aryl substituent, such as benzyl
 or phenethyl, or naphthylpropyl, or an aryl as defined
 above.

Unless otherwise indicated, the term
 "cycloheteroalkyl" as used herein alone or as part of
 25 another group refers to a 5-, 6- or 7-membered saturated or
 partially unsaturated ring which includes 1 to 2 hetero
 atoms such as nitrogen, oxygen and/or sulfur, linked
 through a carbon atom or a heteroatom, where possible,
 optionally via the linker $(CH_2)_p$ (where p is 1, 2 or 3),
 30 such as






and the like. The above groups may include 1 to 3 substituents such as any of the substituents for alkyl or aryl as defined above. In addition, any of the above rings can be fused to 1 or 2 cycloalkyl, aryl, heteroaryl or cycloheteroalkyl rings.

Unless otherwise indicated, the term "heteroaryl" (also referred to as heteroaryl) as used herein alone or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), linked through a carbon atom or a heteroatom, where possible, optionally via the linker $(\text{CH}_2)_p$ (which is defined above), such as

20



and the like.

The heteroaryl groups including the above groups may optionally include 1 to 4 substituents such as any of the substituents listed for aryl. In addition, any of the above rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

The term "prodrug esters" as employed herein includes prodrug esters which are known in the art for both


phosphorus and carboxylic acids such as similar carboxylic acid esters such as methyl, ethyl benzyl and the like. Other examples include the following groups: (1- alkanoyloxy)alkyl such as,

5



wherein R^a, R^b and R^c are H, alkyl, aryl or aryl-alkyl; however R^aO cannot be HO. Examples of such prodrug esters include



10 include




t-C₄H₉CO₂CH₂- , or



15 Other examples of suitable prodrug esters include



20 wherein R^a can be H, alkyl (such as methyl or t-butyl), arylalkyl (such as benzyl) or aryl (such as phenyl); R^d is H, alkyl, halogen or alkoxy, R^e is alkyl, aryl, arylalkyl or alkoxy, and n_1 is 0, 1 or 2; or



(d is 0 to 3)

Where the aP2 inhibitor is in acid form it may form a pharmaceutically acceptable salt such as alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium as well as zinc or aluminum and other cations such as ammonium, choline, diethanolamine, ethylenediamine, t-butylamine, t-octylamine, dehydroabietylamine.

Where desired, the aP2 inhibitor may be used in combination with another antidiabetic agent (also referred to herein as "another antihyperglycemic agent") which may be administered orally in the same dosage form in accordance with the invention, a separate oral dosage form or by injection.

The other antidiabetic agent may be a biguanide, a sulfonyl urea, a glucosidase inhibitor, a thiazolidinedione, an insulin sensitizer, a glucagon-like peptide-1 (GLP-1), insulin or a PPAR α/γ dual agonist.

It is believed that the use of the aP2 inhibitor in combination with another antidiabetic agent produces antihyperglycemic results greater than that possible from each of these medicaments alone and greater than the combined additive anti-hyperglycemic effects produced by these medicaments.

The other antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof.

Where the other antidiabetic agent is a biguanide, the aP2 inhibitor will be employed in a weight ratio to

biguanide within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 2:1.

The other antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as 5 glibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the β -cells, with glyburide being preferred.

10 The aP2 inhibitor will be employed in a weight ratio to the sulfonyl urea in the range from about 0.01:1 to about 100:1, preferably from about 0.2:1 to about 10:1.

15 The oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. Patent No. 4,639,436), which may be administered in a separate oral dosage form.

20 The aP2 inhibitor will be employed in a weight ratio to the glucosidase inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 50:1.

25 The aP2 inhibitor may be employed in combination with a thiazolidinedione oral antidiabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as troglitazone (Warner-Labert's Rezulin[®], disclosed in U.S. Patent No. 4,572,912), rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 30 5,594,016), Glaxo-Welcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer).

35 The aP2 inhibitor will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 5:1.

The sulfonyl urea and thiazolidinedione in amounts of less than about 150 mg oral antidiabetic agent may be incorporated in a single tablet with the αP2 inhibitor.

5 The αP2 inhibitor may also be employed in combination with a non-oral antihyperglycemic agent such as insulin or with glucagon-like peptide-1 (GLP-1) such as GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener, the disclosure of which is incorporated herein by reference),
10 which may be administered via injection, or by transdermal or buccal devices.

Where present, metformin, the sulfonyl ureas, such as glyburide, glimepiride, glipizide, chlorpropamide and gliclazide and the glucosidase
15 inhibitors acarbose or miglitol or insulin may be employed in formulations as described above and in amounts and dosing as indicated in the Physician's Desk Reference.

20 Where present, metformin or salt thereof may be employed in amounts within the range from about 500 to about 2000 mg per day which may be administered in single or divided doses one to four times daily.


25 Where present, the thiazolidinedione antidiabetic agent may be employed in amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day.

30 Where present, insulin may be employed in formulations, amounts and dosing as indicated by the Physician's Desk Reference.

35 Where present, GLP-1 peptides may be administered in oral buccal formulations, by nasal administration or parenterally as described in U.S. Patent Nos. 5,346,701 (TheraTech), 5,614,492 and 5,631,224 which are incorporated herein by reference.

35 The αP2 inhibitor may be employed in combination with another antidiabetic agent which may be a PPAR α/γ dual agonist such as an N-benzyldioxothiazolidylbenzamide

derivative such as disclosed in WO 96/38428 such as 5-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxy-N-[4-(trifluoromethyl)benzyl]benzamide (KRP-297), WO 98/05531 (Ligand Pharmaceuticals, Inc.) which discloses 2-(4-[2,4-difluorophenyl]-1-heptylureido)ethyl phenoxy)-2-methylbutyric acid, and WO 97/25042 and WO 96/04260 (SKB) which disclose benzoxazole and pyridine derivatives of the structure



10

or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein R° represents 2-benzoxazolyl or 2-pyridyl and R¹ represents CH₂OCH₃ or CF₃, such as (S)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-methoxyethoxy)propanoic acid; or (S)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoic acid; or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof. Dosages employed are as set out in the above references.

The aP2 inhibitor will be employed in a weight ratio to the PPAR α/γ dual agonist within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 5:1.

25

Where the aP2 inhibitor is employed in combination with the PPAR α/γ dual agonist, the combination may be

employed in an oral dosage form such as a tablet or capsule as will be apparent to one skilled in the art.

In carrying out the method of the invention, a pharmaceutical composition will be employed containing at least one aP2 inhibitor with or without another antidiabetic agent in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration. The compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations. The dose for adults is preferably between 50 and 2,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.

A typical capsule for oral administration contains aP2 inhibitor (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.

A typical injectable preparation is produced by aseptically placing 250 mg of aP2 inhibitor into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

Compounds sufficiently satisfying the structural criteria described above may be determined by use of an in vitro assay system which measures the potentiation of inhibition of aP2 by displacement of a fluorescent substrate from aP2 by the inhibitor. Inhibition constants (Ki values) for the inhibitors may be determined by the method described below:

35

Production of purified recombinant human aP2 protein. Recombinant human aP2 protein is produced by

standard recombinant DNA technology. In the typical case, aP2 is produced by heterologous expression in *E. coli* strain BL21(D53) transformed with pET11a vector containing the full length human aP2 cDNA (Baxa, C.A., Sha, R.S.,
5 Buelt, M.K., Smith, A.J., Matarese, V., Chinander, L.L., Boundy, K.L., and Bernlohr, D.A. (1989). Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. *Biochemistry* 28: 8683-8690 and Xu, Z., Buelt, M.K., Banaszak, L.J., and Bernlohr,
10 D.A. (1991). Expression, purification and crystallization of the adipocyte lipid binding protein. *J. Biol. Chem.* 266: 14367-14370). Purification of aP2 from *E. coli* is conducted as described by Xu, yielding essentially homogeneous aP2 protein with molecular weight ~14600
15 daltons and free of endogenous fatty acids. The purified aP2 is capable of binding up to one mole of free fatty acid per mole protein. The binding and structural properties of recombinant aP2 protein were previously shown to be identical to aP2 protein isolated from adipose tissue.
20

In vitro assay of aP2 inhibitors. Inhibitors of aP2 are evaluated in a homogeneous fluorescent-based competition assay using recombinant aP2 protein and 1,8-anilino-naphthalene-sulfonic acid (1,8-ANS) as assay
25 substrate. This competition assay was adapted from generalized procedures described previously (Kane, C.D. and Bernlohr, D.A. (1996). A simple assay for intracellular lipid-binding proteins using displacement of 1-anilino-8-sulfonic acid. (1996) *Anal. Biochem.* 233: 197-204 and
30 Kurian E., Kirk, W.R. and Prendergast, F.G. (1996) Affinity of fatty acid for r-rat intestinal fatty acid binding protein. *Biochemistry*, 35, 3865-3874). The method relies on the increase in fluorescence quantum yield of 1,8-ANS upon binding to the fatty acid binding site of aP2. The
35 assay is run using appropriate concentrations of inhibitor, 1,8-ANS, and aP2 protein, in order to calculate the inhibitor binding constant (Ki) for compounds being

evaluated. The Ki calculation was based on the procedure previously described for calculation of dissociation constants described by Kurian. Lower Ki values indicate higher affinities of compounds binding to aP2.

5 In the assay as conducted for the inhibitors described herein, a series of aliquots of aP2 (5 μ M) in solution in 10 mM potassium phosphate buffer (pH 7.0) are mixed with an equimolar concentration of test compound, followed by the addition of a series of increasing
10 concentrations of 1,8-ANS (from 0 to 5 μ M). The assay typically is conducted in 96-well plate format with reagents added using robotic instrumentation (Packard Multiprobe 104). The fluorescence value for each test is determined using a Cytofluor-4000 multi-well fluorescence
15 plate reader (Perceptive Biosystems) using excitation wavelength 360 nm and emission wavelength 460 nm, or using other suitable spectrofluorometer. In preparation for the assay, test compounds are initially prepared at 10 mM in dimethylsulfoxide. All subsequent dilutions and assay
20 additions are made in 10 mM potassium phosphate buffer, pH 7.0.

X-ray crystallography of the inhibitor-aP2 complex can be performed by one skilled in the art using contemporary biophysical methodologies and commercial
25 instrumentation. Such crystallographic data can be used to conclusively determine if a compound used in the present invention has embodied the structural requirement necessary for inhibition of aP2. An example of such an X-ray crystallographic determination is presented below:

30 Crystals of aP2 complexed with the inhibitors were typically grown by the hanging drop method. aP2, at 8.3 mg/ml, was pre-equilibrated with 1-5 mM of the inhibitor in 0.1 M Tris-HCl pH 8.0, 1% w/v DMSO for four hours. 2 μ l drops containing equilibrated protein and reservoir
35 solution at a 1:1 ratio were suspended on plastic cover slips and equilibrated against a 1 ml reservoir containing 2.6-3.0 M ammonium sulfate in 0.1 M Tris-HCl pH 8.0.

Crystals typically appeared in 2-3 days and reached maximum size within 2 weeks. Data was typically collected on a single flash-frozen crystal (Oxford Cryosystems) using a Rigaku rotating anode and an R-axis II image plate detector of a Bruker multiwire area detector. Diffraction from aP2 crystals was excellent. Diffraction was consistently observed to better than 2.0 Å resolution often to beyond 1.5 Å resolution. Data was processed either with DENZO/SCALEPACK (R-axis II data), or Xengen (Bruker data). XPLOR was used for structure refinement and model building was done using the molecular modeling package CHAIN. After a single round of refinement, examination of the $F_o - F_c$ map typically allowed facile building of the inhibitor into aP2 binding cavity. Iterative fitting and refinement were continued until improvement was no longer seen in the electron density map or R-free.

Referring to the accompanying Figure which is a computer generated image of a partial X-ray structure of compound XVIA bound to human aP2, the ball and stick figure in light gray is compound XVIA. The Arg106, Arg126, and Tyr128 residues are depicted as ball and stick figures in dark gray. The dark spheres represent a space filling view of the discrete binding pocket comprised of the residues Phe16, Tyr19, Met20, Val23, Val25, Ala33, Phe57, Thr74, Ala75, Asp76, Arg78. The 4-chlorophenyl substituent of compound XVIA is shown bound within this discrete pocket and the hydroxyl group is bound to the Arg-Tyr-Arg residues.

What is claimed is:

1. A method for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia, or elevated fatty acids, or glycerol, or hypertriglyceridemia which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of an aP2 inhibitor.
2. The method as defined in Claim 1 wherein the aP2 inhibitor binds to the aP2 protein and inhibits its function and/or its ability to bind free fatty acids.
3. The method as defined in Claim 1 wherein the aP2 inhibitor contains a hydrogen bond donator or acceptor group and interacts directly or through an intervening water molecule either by ionic or hydrogen bonding interactions, with one, two, or three of the three amino acid residues, designated as Arg 106, Arg 126 and Tyr 128 in human aP2 within the aP2 protein.
4. The method as defined in Claim 3 wherein the hydrogen bond donator or acceptor group is acid in nature.
5. The method as defined in Claim 3 where said aP2 inhibitor contains an additional substituent which binds to (in) and/or interacts with a discrete pocket within the aP2 protein defined roughly by the amino acid residues Phe 16, Tyr 19, Met 20, Val 23, Val 25, Ala 33, Phe 57, Thr 74, Ala 75, Asp 76, Arg 78 in human aP2.
6. The method as defined in Claim 5 wherein said additional substituent in said aP2 inhibitor is hydrophobic in nature.
7. The method as defined in Claim 5 in which the through space distance from the hydrogen bond donor/acceptor group and the additional substituent group in said aP2 inhibitor is within the distance of about 7 to about 15 Angstroms.
8. The method as defined in Claim 1 wherein Type II diabetes is treated.

9. The method as defined in Claim 1 wherein the aP2 inhibitor is employed in the form of a pharmaceutically acceptable salt thereof or a prodrug ester thereof.

10. The method as defined in Claim 1 wherein the
5 aP2 inhibitor includes an oxazole or analogous ring, a pyrimidine derivative or a pyridazinone derivative.


11. The method as defined in Claim 10 wherein the
aP2 inhibitor is a substituted benzoyl or biphenyl-2-
10 oxazole-alkanoic acid derivative, an oxazole derivative, a 2-thio-4,5-diphenyloxazole S-derivative, a phenyl-heterocyclic oxazole derivative, a diaryloxadiazole derivative, a 4,5-diphenyloxazole derivative, an oxazole carboxylic acid derivative, a phenoxyazolyloxazole derivative, or a 2-(4,5-diaryl)-2-oxazolyl substituted
15 phenoxyalkanoic acid derivative.

12. The method as defined in Claim 10 wherein the aP2 inhibitor is a 2-benzyloxyprymidine derivative, a dihydro(alkylthio)(naphthylmethyl)oxypyrimidine derivative, a thiouracil derivative, or an α -substituted pyrimidine-
20 thioalkyl or alkyl ether derivative.

13. The method as defined in Claim 10 wherein the aP2 inhibitor is a pyridazinone acetic acid derivative.


14. The method as defined in Claim 10 wherein the aP2 inhibitor is

25 (I) a substituted benzoylbenzene or biphenyl alkanoic acid derivative having the structure:




wherein

A is a group having the formula




wherein


X is -N- or



Z is




- 5 R¹ is hydrogen, lower alkyl or phenyl;
 R² is hydrogen or lower alkyl; or
 R¹ and R² taken together form a benzene ring, with
 the proviso that when X is -N-, Z is other than



R³ is hydrogen or lower alkyl;
 n is 1-2;


B is



15 wherein

Y is OR⁵ or N(OH)R⁸;

R⁴ and R⁵ are each, independently, hydrogen or lower alkyl;


R⁶ is hydrogen, halo or nitro;20 R⁷ isR⁸ is lower alkyl;

m is 0-3;

25 or a pharmacologically acceptable salts thereof;

(II) oxazole derivatives which have the structure

II



in which;


5 R and R' are identical or different and represent a hydrogen atom or an alkyl radical containing 1 or 2 carbon atoms,

10 R₁ and R₂ are identical or different and represent hydrogen or halogen atoms or alkyloxy radicals in which the alkyl portion contains 1 to 4 carbon atoms in a straight or branched chain, and

n equals 3 to 6, as well to their salts;

(III) 2-thiol-4,5-diphenyloxazole S-derivatives which have the structure


III



15 wherein m is 0, 1 or 2, n is 1 and R represents hydroxy, alkoxy or amino, and pharmaceutically acceptable addition salts thereof;

(IV) azole derivatives of the structure


IV



20 wherein R₁ is carboxyl, esterified carboxyl or other functionally modified carboxyl group; R₂ and R₃ each are aryl of up to 10 carbon atoms; A is C_nH_{2n} in which n is an integer from 1 to 10, inclusive; and Z is O or S, and physiologically acceptable salts thereof;

(V) phenyl-heterocyclic oxazole derivatives which have the structure

V.




5

R is CH_2R^2 ;

R^1 is Ph or Th;

R^2 is



10


CO_2R^3 ; and

R^3 is H, or C₁-C₄ lower alkyl;

or pharmaceutically acceptable salt thereof;

(VI) diaryloxazole derivatives having the structure

VI




15 wherein R^1 is carboxy or protected carboxy,

R^2 is aryl,

R^3 is aryl,

A^1 is lower alkylene,


A^2 is bond or lower alkylene and
 $-Q-$ is



(in which A^3 is cyclo (lower)alkane or
 cycle(lower)alkene,

each of which may have suitable substituent(s));
 (VII) 4,5-diphenyloxazole derivatives having the
 structure

VIIA



10

wherein

R is H or C₁-C₅ lower alkyl,


X is N or CH,

Y is H or CO₂R¹, or COR², provided that when X is CH,

15 Y is not H,

R¹ is C₁-C₅ lower alkyl, or phenylmethyl, andR² is C₁-C₅ alkyl;

VIIIB



20 wherein

R is H or C₁-C₅ lower alkyl,

X is $(\text{CH}_2)_n$ or para or meta substituted phenyl
wherein the substituent is OR²,


R² is C₁-C₅ alkyl, and

n is an integer of 4 to 8,

5 and pharmaceutically acceptable salts thereof;

(VIII) oxazole carboxylic acid derivatives having
the structure

VIII



10

wherein

Y and Z are independently hydrogen or together form
a bond;

X is CN, CO₂R¹ or CONR²R³;


15 R and R¹ are independently or together H, Na, or
C₁-C₅ lower alkyl;

R² and R³ are independently or together H, or C₁-C₅
lower alkyl;

or alkali metal salt thereof;



20 (IX) phenoxyazolyloxadole derivatives having the
structure

IX



wherein

X is



R⁶

—


R⁷

R⁶

=


R⁷

or




25

Y is CH₃, Ph, or OH, provided that when Y is OH, the compound exists in the keto-enol tautomerism form




- 5 R¹ is Ph or Th;
 R² is CH₂R³;
 R³ is CO₂R⁴;
 R⁴ is H or C₁-C₅ lower alkyl;
 R⁵ is H or CH₃; R⁶ is OHCHN or H₂N; and
 R⁷ is H or OH;
- 10 or pharmaceutically acceptable salt thereof;
 (X) 2-(4,5-diaryl)-2-oxazolyl substituted
 phenoxyalkanoic acids and esters having the structure

XA




15 XB




(wherein n is 7-9 and R is hydrogen or lower alkyl; or when R is hydrogen, the alkali metal salt thereof),

XC



20

XD



wherein


R₁ is phenyl or thienyl;

R₂ is hydrogen, lower alkyl or together with CO₂ is tetrazol-1-yl;

X is a divalent connecting group selected from the group consisting of CH₂CH₂, CH=CH, and CH₂O;

- 5 Y is a divalent connecting group attached to the 3- or 4-phenyl position selected from the group consisting of OCH₂, CH₂CH₂ and CH=CH,
 or when R₂ is hydrogen, an alkali metal salt thereof;
 (XI) substituted 4,5-diaryl heterocycles having the
 10 formula


XI



in which

- each group Ar is the same or different and is
 15 optionally substituted phenyl or optionally substituted heteroaryl;
 X is nitrogen or CR¹;
 Y is nitrogen, N(CH₂)_nA or C(CH₂)_nA;
 Z is nitrogen, oxygen or N(CH₂)_nA, and the dotted
 20 line indicates the optional presence of a double bond so as to form a fully unsaturated heterocyclic ring;
 R¹ is hydrogen, C₁₋₄alkyl, optionally substituted phenyl or optionally substituted heteroaryl;
 n is 4 to 12; and
 25 A is CO₂H or a group hydrolysable to CO₂H, 5-tetrazolyl, SO₃H, P(O)(OR)₂, P(O)(OH)₂, or P(O)(R)(OR) in which R is hydrogen or C₁₋₄alkyl, or a pharmaceutically acceptable salt thereof;
 (XII) compounds which have the structure

30 XII



Where X is O or S;


R₁ is H, phenyl or phenyl substituted with F, Cl or Br or alkoxy,

R₂ is H, alkyl, phenyl or phenyl substituted with F, Cl or Br or alkoxy, and

5 R₃ is H or alkyl;

(XIII) 2-benzyloxypyrimidine derivatives having the following structure

XIII



10 wherein


R¹ and R² are each independently H, a halogen, hydroxyl, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₅ alkenyl, C₃-C₅ alkynyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₃-C₅ alkenyloxy, C₃-C₅ alkynyloxy, C₁-C₄ alkylthio, or phenyl, with the proviso that at least one of R¹ and R² must be hydroxyl;

15 n is an integer of 0 to 5; and
each X which may be identical or different if n is greater than 1, is a halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₇-C₉ aralkyloxy, phenyl,

20 hydroxymethyl, hydroxycarbonyl, C₁-C₄ alkoxy carbonyl, or nitro;

(XIV) dihydro(alkylthio)-(naphthylmethyl)-oxopyrimidines which have the structures


XIVA




3a R=sec-butyl
3b R=cyclopentyl
3c R=cyclohexyl

25

XIVB




XIVC




5

XIVD




XIVE



- 10 R¹ = sec-butyl, cyclopentyl, cyclohexyl;
 R² = H, CH₃, including tautomers of the above;


(XVI) α -substituted pyrimidine-thioalkyl and alkylether compounds which have the structure

XVI



5 where m is 0 or 1;

R¹ is selected from -CO₂R₅₃, -CONR₅₄R₅₅,



10 where s is 0 or 1, and R₂₀, R₂₁, R₂₂, R₂₃, R₂₄, and R₂₅ are the same or different and are selected from -H, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₃-C₈ cycloalkyl, -CF₃, -NO₂, -halo, -OH, -CN, phenyl, phenylthio, -styryl, -CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁), -(CH₂)_n-N(R₃₁)(R₃₂), -C(OH)(R₃₁(R₃₃), -(CH₂)_nN(R₃₁)(CO(R₃₃)), (CH₂)_nN(R₃₁)(SO₂(R₃₃)), or where R₂₀ and R₂₁, or R₂₁ and R₂₂, or R₂₂ and R₂₃ are taken together to form a five or six-membered saturated or unsaturated ring containing 0 or 1 oxygen, nitrogen or sulfur, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, -(CH₂)_n-N(R₃₁)(R₃₂), -C₃-C₈ cycloalkyl, -CF₃, -halo, CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁), -(CH₂)_nN(R₃₁)(CO(R₃₃)), -(CH₂)_nN(R₃₁)(SO₂(R₃₃)), -CN, -CH₂CF₃ or -CH(CF₃)₂, or phenyl and the saturated ring may be optionally substituted with 1, 2 or 3, -C₁-C₆ alkyl, -C₁-C₆ alkoxy, -OH, -CH₂OH or -(CH₂)_n-N(R₃₁)(R₃₂) or one oxo (=O); where n is 0-3 and R₃₁, R₃₂ and R₃₃ are the same or different and are selected from -H, C₁-C₆ alkyl,


phenyl optionally substituted with 1, 2 or 3 -halo,
C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH or -CN,
or where R₃₁ and R₃₂ taken together with the attached
nitrogen to form a ring selected from -pyrrolidinyl, -
5 piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-
piperazinyl, -4-(1-C₁-C₆alkyl)piperazinyl, or a member
selected from
1-cyclohexenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-
pyrimidinyl, 2-imidazolyl, 4-imidazolyl, 2-benzothiazolyl,
10 2-benzoxazolyl, 2-benzimidazolyl, 2-oxazolyl, 4-oxazolyl,
2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 5-methyl-3-
isoxazolyl, 5-phenyl-3-isoxazolyl, 4-thiazolyl, 3-methyl-2-
pyrazinyl, 5-methyl-2-pyrazinyl, 6-methyl-2-pyrazinyl, 5-
chloro-2-thienyl, 3-furyl, benzofuran-2-yl, benzothien-2-
15 yl, 2H-1-benzopyran-3-yl, 2,3-dihydrobenzopyran-5-yl, 1-
methylimidazol-2-yl, quinoxalin-2-yl, piperon-5-yl, 4,7-
dichlorobenzoxazol-2-yl, 4,6-dimethylpyrimidin-2-yl, 4-
methylpyrimidin-2-yl, 2,4-dimethylpyrimidin-6-yl, 2-
methylpyrimidin-4-yl, 4-methylpyrimidin-6-yl, 6-
20 chloropiperon-5-yl, 5-chloroimidazol[1,2-a]pyridin-2-yl, 1-
H-inden-3-yl, 1-H-2-methyl-inden-2-yl, 3,4-dihydronaphth-1-
yl, S-4-isopropenylcyclohexen-1-yl or 4-dihydronaphth-2-yl;
where R₅₃ is selected from -H, C₁-C₆alkyl, C₃-
C₆cycloalkyl, phenyl (optionally substituted with 1, 2, or
25 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH, -CN), or a
five or six-membered unsaturated ring containing 0 or 1
oxygen, nitrogen or sulfur, where the unsaturated ring may
be optionally substituted with -H, C₁-C₆ alkyl, C₁-C₆
alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂);
30 where R₅₄ and R₅₅ being the same or different are
selected from -H, C₁-C₆ alkyl, allyl, or phenyl (optionally
substituted with 1, 2 or 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy
or -CF₃), or taken together with the attached nitrogen to
form a ring selected from -pyrrolidinyl, -piperidinyl, -4-
35 morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, -4-(1-C₁-
C₆alkyl)piperazinyl;

- R₄₁ and R₄₂, being the same or different, are selected from -H and C₁-C₄ alkyl;
- R₁₂ is selected from -H, C₁-C₆ alkyl, -C₃-C₆ cycloalkyl, -CN, -C(O)NH₂, -C(O)N(C₁-C₆alkyl)(C₁-C₆alkyl), -CO₂H, -CO₂(C₁-C₆alkyl), -CH₂OH, -CH₂NH₂ or -CF₃;
- R₁₃ is selected from -H, C₁-C₆ alkyl or -CF₃;
- Y is selected from -S-, -S(O)-, -S(O)₂, or -O-;
- R₄ is -OH;
- R₅ is selected -H, -C₂H₄OH, -C₂H₄-O-TBDMS, halo, -C₃-C₆ cycloalkyl, C₁-C₃ alkoxy, -CH₂CH₂Cl or C₁-C₄ alkyl, with the proviso that R₅ is not isobutyl;
- or, when R₆ is hydroxyl, R₄ and R₅ are taken together to form a five or six-memebered saturated or unsaturated ring which together with the pyrimidine ring form the group consisting of 7H-pyrrolo[2,3-d]pyrimidine, 5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidine, furo[2,3-d]pyrimidine, 5,6-dihydro-furo[2,3-d]pyrimidine, thieno[2,3-d]pyrimidine, 5,6-dihydro-thieno[2,3-d]pyrimidine, 1H-pyrazolo[3,4-d]pyrimidine, 1H-purine, pyrimido[4,5-d]pyrimidine, pteridine, pyrido[2,3-d]pyrimidine, or quinazoline, where the unsaturated ring may be optionally substituted with 1, 2 or 3, C₁-C₆ alkyl C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂), -C₃-C₈ cycloalkyl, -CF₃, -halo, -CO₂(R₃₁), -CON(R₃₁)(R₃₂), -CO(R₃₁), -(CH₂)_nN(R₃₁)(CO(R₃₃)), -(CH₂)_nN(R₃₁)(SO₂(R₃₃)), and the saturated ring may be optionally substituted with 1, 2 or 3, -C₁-C₆ alkyl, C₁-C₆ alkoxy, -OH, -CH₂OH, or -(CH₂)_n-N(R₃₁)(R₃₂) or one oxo (=O); and
- R₆ is selected from -H, -OH, halo, -CN, -CF₃, -CO₂(R₆₁), -C(O)R₆₁ or -C(O)N(R₆₁)(R₆₂) where R₆₁ and R₆₂ are the same or different and are selected from -H, C₁-C₆ alkyl, phenyl optionally substituted with 1, 2 or 3 -halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, -OH, -CN, or where R₆₁ and R₆₂ taken together with the attached nitrogen to form a ring selected from -pyrrolidinyl, -


piperidinyl, -4-morpholinyl, -4-thiomorpholinyl, -4-piperazinyl, or -4-(C₁-C₆ alkyl)piperazinyl;

pharmaceutically acceptable salts, hydrates, N-oxides and solvates thereof;

5 (XVII) compounds which have the structure




XVIIA






XVIIB

- where R₁ and R₂ are H, alkyl, aryl or arylalkyl, where the alkyl can include as substituents halogen, CF₃, CH₃O, CH₃S, NO₂, or R₁ and R₂ with the carbons to which they are attached can form methylenedioxy, or
 10 R₁ and R₂ can form a C₃-C₇ non-aromatic ring, or a heterocycle which can be pyridine, pyrazine, pyrimidine, pyridazine, indol, or pyrazole, or an oxygen containing heterocycle which can be pyran or furan, or a sulfur containing heterocycle which can be thiopyran, or thiophene; the heterocycles being optionally substituted with halogen or alkyl,
 15 R₃ and R₄ are H, alkyl, halogen, CF₃, CH₃O, CH₃S or NO₂ or R₃ and R₄ with the carbons to which they are attached can form a methylenedioxy group,
 20 R₅ is H, and
 Z is a heterocycle which can be pyridine, thiazole, benzothiazole, benzimidazole or quinoline, which Z group
 25 can optionally be substituted with halogen or alkyl.

15. The method as defined in Claim 1 wherein the aP2 inhibitor has the structure



5



10

16. A pharmaceutical combination comprising an α P2 inhibitor and another type antidiabetic agent.

5 17. The combination as defined in Claim 16 wherein the antidiabetic agent is a biguanide, a sulfonyl urea, a glucosidase inhibitor, a thiazolidinedione, an insulin sensitizer, a glucagon-like peptide-1 (GLP-1), insulin, a PPAR α/γ dual agonist and/or a meglitinide.

10 18. The combination as defined in Claim 16 wherein the antidiabetic agent is metformin, glyburide, glimepiride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, troglitazone, insulin, KRP-297, repaglinide and/or nateglinide.

15 19. The combination as defined in Claim 16 wherein the α P2 inhibitor is present in a weight ratio to the antidiabetic agent within the range from about 0.01 to about 100:1.

20 20. A method for treating insulin resistance, diabetes, obesity, hyperglycemia, hyperinsulinemia, or elevated blood levels of free fatty acids, or glycerol, or hypertriglyceridemia, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 16.


25

METHOD FOR TREATING DIABETES EMPLOYING AN aP2
INHIBITOR AND COMBINATION

Abstract of the Disclosure

5 A method is provided for treating diabetes and related diseases, especially Type II diabetes, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

10



FIGURE

DECLARATION
AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION, the specification of which

x is attached hereto; or

 was filed on as U.S. Patent Application Serial No.
 / .

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIORITY FOREIGN APPLICATION(S)
UNDER 35 U.S.C. §119(a)-(d)

Number	Country	Filed (Day/month/year)	Priority Claimed (Yes or No)
NONE			

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

PRIORITY U.S. PROVISIONAL APPLICATION(S)
UNDER 35 U.S.C. §119(e)

Provisional Application No. 60/100,677	Filing Date 09/17/98
---	-------------------------

Continued on page 2

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of this application as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

PRIORITY U.S. APPLICATION(S)
UNDER 35 U.S.C. §120

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status (patented, pending or abandoned)</u>
NONE		

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Burton Rodney	Registration No. 22,076
Stephen B. Davis	Registration No. 26,693
Suzanne E. Babajko	Registration No. 32,880
Barry J. Marenberg	Registration No. 40,715
Joan E. Switzer	Registration No. 34,740
Ronald S. Hermenau	Registration No. 34,620

Address all telephone calls to:

Tel. No. (609) 252-4336

Address all correspondence to:

Burton Rodney
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, New Jersey 08543-4000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Continued on page 3

Full name of sole or first Inventor

Jeffrey A. Robl

Inventor's signature:



Date: 8-11-99

Residence: Newtown, Pennsylvania


Citizenship: United States

Post Office Address: 7 Tulip Drive
Newtown, PA 18940

Full name of second Inventor, if any

Rex A. Parker

Inventor's signature:


Date: 8-11-99

Residence: Titusville, New Jersey


Citizenship: United States

Post Office Address: 147 Church Road
Titusville, NJ 08560

Full name of third Inventor, if any

Scott A. Biller

Inventor's signature:


Date: 8/11/99

Residence: Hopewell, New Jersey

Citizenship: United States

Post Office Address: 31 Second Street
Hopewell, NJ 08525

Continued on page 4

Full name of fourth Inventor, if any

Haris Jamil

Inventor's signature:

Haris Jamil

Date: 8/11/99

Residence: Newtown, Pennsylvania

Citizenship: Canada

Post Office Address: 239 Burgundy Lane
Newtown, PA 18940

Full name of fifth Inventor, if any

Bruce L. Jacobson

Inventor's signature:

Bruce L. Jacobson

Date: 8/11/99

Residence: Mercerville, New Jersey

Citizenship: United States

Post Office Address: 368 Vetterlein Avenue
Mercerville, NJ 08619

Full name of sixth Inventor, if any

Krishna Kodukula

Inventor's signature:

Krishna Kodukula

Date: 8-23-99

Residence: Princeton, New Jersey

Citizenship: India

Post Office Address: 33 Douglass Drive
Princeton, NJ 08540